

# Overview

17	Supervisory Board Report
26	Executive Committee
30	Common Shares

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**
**Corporate Governance Report**
**Environmental, Social  
and Governance**
**Financial Results**
**Appendix**

# Overview

## Supervisory Board Report

### Message from the Chair

Dear Stakeholders:

It is a pleasure to share with you this update on the progress of QIAGEN on behalf of our more than 6,000 employees, our Managing Board and my colleagues in the Supervisory Board.

Building on the events in 2020, the contributions of QIAGEN to society during 2021 has never been more critical as the response to the global pandemic took on new dimensions that were unpredictable at the start of the year.

The Supervisory Board continues to be impressed by how our QIAGENers are responding to the challenges facing us worldwide with a courageous, collaborative and caring spirit. They have again showed what a truly agile and robust company we have in terms of delivering a year with record results. Above all, they are moving forward toward achieving our vision of helping to make improvements in life possible.

We would also like to thank our shareholders, customers, business partners and other stakeholders for honoring QIAGEN with their continued collaboration and trust. Together we have delivered an outstanding performance in 2021 and look forward to executing on our strategy in 2022 and beyond.

### 2021: Another year of record results

During a year of volatile trends due the pandemic, QIAGEN delivered an outstanding performance in 2021. Net sales rose 20% to \$2.25 billion, while profitability improved at a faster pace as adjusted earnings per share (EPS) were up 23% to \$2.65. (Adjusted EPS excludes purchased intangibles amortization, long-lived asset impairments and other items such as business integration, acquisition-related costs, litigation costs and restructuring.)

It was indeed a year in which QIAGEN continued to show that it was very relevant for the global response to the pandemic, but not dependent on COVID-19 to grow and create value. The Supervisory Board was closely involved in monitoring the impact of the pandemic on QIAGEN, and supported the decision of the Managing Board to adjust the outlook for 2022 to focus on trends for the non-COVID portfolio and take a more cautious view on volatile COVID-19 testing trends. It is particularly important to recognize the 22% CER growth in our non-COVID product portfolio, which was above the target for 20% CER sales growth in 2021.

### Executing on our strategy

QIAGEN is moving ahead to implement a strategy that involves “focus” and “balance” while targeting growth opportunities in an \$11 billion market opportunity.

This strategy is anchored in our absolute leadership in Sample technologies, which are used to isolate and purify DNA and RNA – the building blocks of life – from any biological sample, and to develop leading positions in markets that can serve over 500,000 customers worldwide.

**Overview**[Supervisory Board Report](#)[Executive Committee](#)[Common Shares](#)**Management Report****Corporate Governance Report****Environmental, Social  
and Governance****Financial Results****Appendix**

A key element of this strategy is to focus on five pillars of growth, which address markets with significant potential and ones in which QIAGEN can achieve / maintain a leading position. We are pleased to see the progress of QuantiFERON-TB as the gold standard for the detection of tuberculosis, as well as the uptake of our newer systems with QIAstat-Dx for syndromic testing, the integrated PCR testing platform NeuMoDx and our entry into digital PCR with QIAcuity.

This strategy also includes developing a business balanced on supporting customers across the continuum from molecular research in the Life Sciences to the use of Molecular Diagnostics in clinical healthcare.

We are also working to develop a balanced global footprint, building up our presence in fast-growing emerging markets as well as in more mature markets.

Another element of our strategy is developing the culture of QIAGEN through the EMPOWER initiative. We want to enhance and strengthen our culture to reach a greater level of accountability and agility with the organization, while also seeking to have decision-making closer to customers intertwined with a new level of accountability to make the best decisions in the interests of our customers and QIAGEN.

My colleagues and I in the Supervisory Board fully endorse this strategy and look forward to supporting and advising the Managing Board on implementation. Indeed, QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. As we focus on even greater value creation, QIAGEN has a disciplined capital allocation policy anchored by a healthy balance sheet to support investment in our business along with a commitment to increasing returns to shareholders.

**Changes in Supervisory Board composition**

As noted in the Supervisory Board report for 2020, we successfully expanded our Supervisory Board with the appointment of two new members with international healthcare and general management experience in early 2021.

We greatly appreciate the contributions of our new colleagues – Thomas Ebeling and Dr. Toralf Haag – and welcome the expertise, international experience and collaborative spirit that they have each brought to QIAGEN. The positive impact has been seen in the effectiveness and level of discussions within the Supervisory Board, as well as the contributions they quickly made to supporting and advising the Managing Board.

These appointments underscore our commitment to creating a Supervisory Board with qualified, experienced and independent members. We have a holistic understanding of diversity that brings together age, gender, qualifications, international experience, cultural backgrounds, sector experience and tenure. These factors should reflect the structure and nature of QIAGEN in order to make better-informed decisions.

As an outcome of our discussions within the Board about the current composition, we initiated in early 2022 a search to find a new, additional Supervisory Board member, and the preference would be for a very experienced professional with a significant track record in our industry.

**Developing deeper insights with our new Scientific Advisory Board**

A company like QIAGEN thrives from dynamic developments in science and seeks to remain at the cutting edge in Life Sciences and Molecular Diagnostics. To ensure that QIAGEN can develop an even stronger position, and to take early advantage of emerging opportunities, the Managing Board and Supervisory Board created in 2021 a new Scientific Advisory Board (SAB), chaired by Prof. Dr. Ross Levine from our Supervisory Board.

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report****Corporate Governance Report****Environmental, Social  
and Governance****Financial Results****Appendix**

The SAB has a mandate to provide early evaluation of market and technology developments that could have an influence on our development and positioning in highly attractive markets. We have welcomed a group of renown scientific leaders to the SAB, each providing unique expertise but joined together by a commitment to harnessing the power of breakthroughs to advance science and improve clinical outcomes for patients. The discussions in this group, and the insights they have provided to the Managing Board and Supervisory Board, have already proven their value to QIAGEN, and we look forward to greater contributions in the future.

**Increasing our commitment to sustainability**

QIAGEN is continually increasing its focus on ESG (environment, social and governance) topics. This is backed by our decision in 2021 to expand the scope of our Nomination Committee to also include ESG topics. These are increasingly discussed with management in our Supervisory Board meetings.

The key aspects of our environmental initiatives focus on addressing climate change, a topic that we recognize requires urgent global action. We announced in 2021 our commitment to reduce carbon emissions by setting science-based targets to reach net zero emissions by 2050. This includes achieving by 2030 an at least 40% reduction in Scope 1 and 2 emissions (direct emissions from QIAGEN), along with a 10% reduction in Scope 3 emissions (a broader definition that involves customers and other factors), on the way to achieving this target. QIAGEN has also recently launched the QIAwave portfolio of environmentally friendly products that reduce the use of plastics by up to 63% and cardboard by up to 42% compared to standard QIAGEN kits. Three types were launched in 2021 in this new portfolio, which will help support further reductions in transportation packaging on top of the 9% reduction in plastic transportation packaging in 2021.

In our focus on social responsibility, it is our duty to protect our employees – especially to keep them safe during the COVID-19 pandemic – as well as the health and safety of the communities in which we operate. Another key initiative in this area has been to steadily increase the share of women in management roles, and this stood at 34% of all managers at the end of 2021.

In the area of governance, we have well-established systems in place, and I want to again highlight the continuing excellent levels of collaboration and trust between the Managing Board and Supervisory Board members. In addition, we have significantly increased the level of awareness about compliance topics, as well as participation in compliance training.

**Moving ahead in 2022 in a dynamic environment**

We look forward to 2022 with confidence amid a dynamic and uncertain environment, including the political, economic and social turmoil created by the Russian invasion of Ukraine. This comes as the spread of COVID-19 continues at levels never imagined at the start of this pandemic two years ago.

Against this backdrop, the Supervisory Board believes QIAGEN has the right strategy to create value for all stakeholders by sharpening our focus on targeted growth opportunities in Life Sciences and Molecular Diagnostics. And we proudly recognize the great efforts made by our QIAGENers during these turbulent times.

The devastating impact of the war in Ukraine has again brought out the best in our employees worldwide through their donations, as well actions on the Ukraine border to support refugees from our organizations nearby in Poland, Romania and Austria. We are proud and pleased to see this level of engagement.

In closing, we view our performance in 2021 as one that we can all truly be proud of. We look forward to even more success in the new year, and the years to come, as we position QIAGEN to achieve our vision of making even more improvements in life possible.

Lawrence A. Rosen

Chair of the Supervisory Board

**Overview**
[Supervisory Board Report](#)
[Executive Committee](#)
[Common Shares](#)
**Management Report**
**Corporate Governance Report**
**Environmental, Social and Governance**
**Financial Results**
**Appendix**
**Supervisory Board composition**

The composition of our Supervisory Board is diverse in gender, nationality, background, knowledge and experience. The Board is comprised of five men and two women. Three members are American, two are German, one is UK-American and one is German-Swiss. Many have spent considerable time during their careers living and working outside their home countries.

The Board's current members are Lawrence A. Rosen (Chair), Dr. Metin Colpan, Thomas Ebeling, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Prof. Dr. Elaine Mardis and Elizabeth E. Tallett. Detailed biographical information can be found in the Corporate Governance Report included in this Annual Report.

Following best practice 2.1.10 of the Dutch Corporate Governance Code, the Supervisory Board establishes that its members are able to act critically and independently of one another on the Managing Board. To safeguard this, the Supervisory Board is composed in such a way that all its members are independent in the meaning of best practice 2.1.8 of the Dutch Corporate Governance Code. As a result, the Supervisory Board confirms being of the opinion that the independence requirements referred to in best practice 2.1.7 to 2.1.9 inclusive of the Dutch Corporate Governance Code have been fulfilled.

The targeted profile of the Supervisory Board is reflected in its regulations, which are published on our website under "Supervisory Board." In terms of members who have a longer tenure, Dr. Metin Colpan joined the Supervisory Board in 2004 and Ms. Elizabeth Tallett has been a Supervisory Board member since 2011. We highly value the scientific and commercial experience of Dr. Colpan and his in-depth knowledge of QIAGEN and the broad industry knowledge, management and board experience of Ms. Tallett. QIAGEN therefore supports the reappointment of Dr. Colpan and Ms. Tallett beyond the eight-year term as recommended by the Dutch Code.

During 2021, the Board changed the scope and composition of its four committees to cover key areas in greater detail, especially Environment, Social and Governance (ESG) and Human Resources topics. The charters of the committees are published on our website under "Supervisory Board."

The following table outlines the current members in 2021:

	Lawrence A. Rosen (Chair)	Dr. Metin Colpan	Thomas Ebeling	Dr. Toralf Haag	Prof. Dr. Ross Levine	Prof. Dr. Elaine Mardis	Elizabeth E. Tallett
Age	64	67	62	55	50	59	72
Gender	Male	Male	Male	Male	Male	Female	Female
Nationality	U.S.	German	Swiss / German	German	U.S.	U.S.	U.S. / British
Date of appointment	2013	2004	2021	2021	2016	2014	2011

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**

**Financial Results**

**Appendix**

The following table outlines the committee membership and meetings attended in 2021:

	Meeting Attendance				
	Supervisory Board	Audit Committee	Compensation & Human Resources Committee	Nomination & ESG Committee	Science & Technology Committee
Lawrence A. Rosen	5/5	7/7	5/5	2/2 (Chair)	
Dr. Metin Colpan	5/5			2/2	4/4 (Chair)
Thomas Ebeling	4/4			2/2	
Dr. Toralf Haag	5/5	7/7 (Chair)			
Dr. Ross L. Levine	5/5				4/4
Dr. Elaine Mardis	5/5		5/5		4/4
Elizabeth E. Tallett	5/5	6/7	5/5 (Chair)	2/2	

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**
**Corporate Governance Report**
**Environmental, Social and Governance**
**Financial Results**
**Appendix**

The following table outlines the skills and experience of the current Supervisory Board members:

Key competencies	Lawrence A. Rosen (Chair)	Dr. Metin Colpan	Thomas Ebeling	Dr. Toralf Haag	Prof. Dr. Ross Levine	Prof. Dr. Elaine Mardis	Elizabeth E. Tallett
<b>Required</b>							
Integrity	•	•	•	•	•	•	•
Ethics	•	•	•	•	•	•	•
Health	•	•	•	•	•	•	•
English language skills	•	•	•	•	•	•	•
Experience	•	•	•	•	•	•	•
<b>Recommended</b>							
U.S. background	•				•	•	•
Entrepreneur		•	•		•		•
Corporate management multinational	•	•	•	•			•
Currently full-time employed / active				•	•	•	
Public reputation	•	•	•	•	•	•	•
Independence	•	•	•	•	•	•	•
Academic research		•			•	•	
Industrial research		•					
Diagnostics markets		•		•		•	
Capital markets	•	•	•	•			•
Financial management	•			•			•
M&A, business development	•	•	•	•			•
Commercial operations		•	•	•			•
Public management (e.g. universities)		•			•	•	
Regulatory / operations		•	•	•			•

**Relationship and stakeholder management**

The Supervisory Board acts in accordance with the interests of the company and the business connected with it, taking into consideration the interests of our stakeholders. The Chair of the Supervisory Board is in regular close contact with the Managing Board members, and the same applies to the Chair of the Audit Committee.

The Supervisory Board recognizes that the pandemic has forced the implementation of new ways to interact, and welcomes how these new approaches have proved beneficial to ensuring a high level of engagement and interaction.

At the same time, the Supervisory Board looks forward to holding more in-person meetings in 2022 at QIAGEN sites around the world, as allowed by local regulations.

**Overview**[Supervisory Board Report](#)[Executive Committee](#)[Common Shares](#)**Management Report****Corporate Governance Report****Environmental, Social  
and Governance****Financial Results****Appendix**

The Supervisory Board interacts with QIAGEN employees on various occasions and in various contexts, and this was done primarily on a virtual basis in 2021 due to the pandemic. They regularly receive information on relevant topics from senior leaders and experts, both internally and externally, during committee meetings, full Supervisory Board meetings, and also as part of their ongoing professional education.

Direct, one-to-one contact between Supervisory Board members and Managing Board and Executive Committee members generally builds on the topics discussed in the meetings of the Supervisory Board. These discussions draw on the expertise of individual Supervisory Board members, whose advice is sought on a wide range of topics. Supervisory Board members also have direct contact with other employees in the course of supporting business operations and in specifically arranged meetings.

In 2021, meetings were generally held virtually due to the pandemic, while any in-person meetings were done in line with local safety measures. These included in particular the onboarding for Mr. Ebeling and Dr. Haag as new members who joined the Supervisory Board in early 2021.

The Supervisory Board takes an active interest in maintaining an in-depth understanding of our stakeholders and their positions on various topics related to QIAGEN's areas of business.

This includes the perceptions of our shareholders, which is received through direct interaction and calls with major institutional shareholders. The Supervisory Board is also informed of the position of the range of QIAGEN stakeholders by the Managing Board and other senior managers. In addition, the Supervisory Board members collect information through their own individual networks, and this is shared with other members and the Managing Board.

**Corporate governance**

The Supervisory Board follows the principle of increasing stakeholder value as the members represent the interests of all stakeholders, including shareholders, and has always pursued the highest standards in corporate governance.

QIAGEN is committed to a corporate governance structure that best suits its business and stakeholders, and that complies with relevant rules and regulations. QIAGEN follows the principles described in the Dutch Corporate Governance Code, although some minor deviations, which are explained in detail in our Corporate Governance Report, may result from the impact of factors such as legal requirements imposed on QIAGEN or industry standards.

Our common shares are registered and traded in the U.S. on the New York Stock Exchange (NYSE) and in Germany on the Frankfurt Stock Exchange in the Prime Standard segment. Shareholders in Europe and the U.S. hold the majority of common shares. As a result of these listings for its Global Shares, QIAGEN is subject to the rules regarding Corporate Governance set by the NYSE. QIAGEN believes all of its operations are carried out in accordance with legal frameworks, including Dutch Corporate Law, U.S. laws and regulations, EU regulations and applicable German capital market laws.

**Role of the Supervisory Board**

The Supervisory Board performs its duties of supervising and advising the Managing Board with respect both to recurring standard agenda items for Supervisory Board meetings and to specific topics that become relevant at any given point in time.

The most prominent regular agenda item is an update on business performance, financial results, treasury and investor relations topics. As part of this agenda item, the Supervisory Board tracks the company's financial performance, approves the annual budget, is updated on capital markets perceptions and expectations, and deliberates on any additional topics as needed.



**Overview**[Supervisory Board Report](#)[Executive Committee](#)[Common Shares](#)**Management Report****Corporate Governance Report****Environmental, Social  
and Governance****Financial Results****Appendix**

In light of the COVID-19 pandemic, significant time was spent on business continuity as well as progress on the implementation of QIAGEN's strategy focused around delivering mid-term growth, in particular from the five pillars of growth. In 2021, the Supervisory Board also discussed and approved a \$100 million share repurchase program that was completed during the year.

In line with its role, the Supervisory Board oversaw the strategy of QIAGEN by regularly reviewing with Management our progress toward strategic objectives, and by debating and endorsing important resource allocation decisions. These discussions also included regularly discussing M&A opportunities and relevant developments within our sectors. The Supervisory Board was actively informed about several potential M&A targets during the year, although none of these have yet to come to fruition. The Supervisory Board was additionally involved in reviewing the development of talent and succession planning within QIAGEN, and in particular monitoring and debating the succession planning initiatives for senior management roles.

**Supervisory Board meetings**

In 2021, the Supervisory Board held a total of five regular meetings, of which one was held in person at our headquarters in Venlo, the Netherlands, and four were held virtually due to the COVID-19 pandemic. These regular meetings included the participation of the Managing Board and Executive Committee members, as well as other QIAGEN managers.

The Supervisory Board also met to review and discuss agenda items in the absence of the Managing Board members, such as management performance and strategy as well as to discuss compensation matters.

All members of the Supervisory Board had adequate time available to devote themselves to their responsibilities.

**Supervisory Board evaluation**

The Supervisory Board conducted a detailed annual survey among its members to evaluate the functioning of the Supervisory Board, its individual members, its Committees, the Managing Board and the individual members of the Managing Board by means of an online survey. The evaluation process was prepared and monitored by the Nomination & ESG Committee, which also conducted an in-depth analysis of the results that were shared with the Supervisory Board and the Managing Board.

Overall, the Supervisory Board concluded that its activities and responsibilities were all being carried out properly and effectively, especially in view of the regulations set forth in the Dutch Corporate Governance Code, and should continue in the same manner.

The overall feedback from the evaluation in 2021 was again very positive. All topics (team composition, meetings, committees, people processes, agenda definition, etc.) received very high scores. Supervisory Board members appreciate the atmosphere within the Board, as well as the collaborative and constructive engagement with the Managing Board that is built on mutual trust and appreciation for their roles and responsibilities to QIAGEN. All members feel heard, valued and trusted, and appreciate the distinctive strengths of the individual members.

**Financial statements and audits**

In this Annual Report, the financial statements for 2021 are presented as prepared by the Managing Board and audited by KPMG Accountants N.V. (Independent Registered Public Accounting Firm). The Audit Committee examined the financial statements, the proposal for the use of the distributable profit, the consolidated financial statements and the Management report. The Supervisory Board also confirmed that the external auditor acted independently.

**Overview**[Supervisory Board Report](#)[Executive Committee](#)[Common Shares](#)**Management Report****Corporate Governance Report****Environmental, Social  
and Governance****Financial Results****Appendix**

The results have been approved by the Supervisory Board and an unqualified opinion was received from the external auditors.

The Supervisory Board will submit the 2021 financial statements to the next Annual General Meeting of Shareholders, which is planned for June 2022. The proposal will recommend that shareholders adopt them and release the Managing Board from all liability in respect of its managerial activities and to release the Supervisory Board from all liability in respect of its Supervisory Board activities.

Venlo, the Netherlands

April 2022

The Supervisory Board

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**

**Financial Results**

**Appendix**

## Executive Committee



**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**

**Financial Results**

**Appendix**

The following is a brief summary of the background of each of the Executive Committee members as of April 1, 2022.



**Thierry Bernard**

Chief Executive Officer and Managing Director

Gender: Male

Thierry Bernard joined QIAGEN in February 2015 to lead QIAGEN’s growing presence in Molecular Diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020, after having previously served in this role on an interim basis. Mr. Bernard previously worked at bioMérieux SA, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Mr. Bernard was appointed in 2020 as a member of the Board of Directors of T2 BioSystems, Inc., a publicly listed company in the U.S. Mr. Bernard has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics, and the College of Europe and is a member of French Foreign Trade Advisors.



**Roland Sackers**

Chief Financial Officer and Managing Director

Gender: Male

Roland Sackers joined QIAGEN in 1999 as Vice President of Finance and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Mr. Sackers earned his Diplom-Kaufmann from the University of Münster, Germany. Mr. Sackers was appointed in 2021 as Vice Chair of the Supervisory Board of Evotec SE, a publicly listed company in Germany and has been a member of the Supervisory Board and Chair of the Audit Committee since 2019. He is also a board member of the industry association BIO Deutschland in Germany.

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**

**Financial Results**

**Appendix**



**Stephany Foster**

Senior Vice President, Head of Human Resources

Gender: Female

Stephany Foster joined QIAGEN in 2005 as Head of Global Internal Audit and was most recently Vice President, Head of Human Resources. Ms. Foster was also member of the NAELT (North America Executive Leadership Team) and steers the Diversity and Inclusion program at QIAGEN. She was named to her current role in October 2019. Prior to joining QIAGEN, Stephany Foster worked in internal audit at Morgan Franklin and Independence Air. She started her career at PricewaterhouseCoopers, specializing in Sarbanes Oxley Auditing. Ms. Foster has a master’s degree in Accounting from the University of Notre Dame and is a Certified Public Accountant (CPA), a Certified Internal and Information Systems Auditor (CIA / CISA) and Certified Fraud Examiner (CFE).



**Antonio M. Santos**

Senior Vice President, Head of Global Operations

Gender: Male

Antonio M. Santos joined QIAGEN in April 2022 as Senior Vice President, Global Operations, and a member of the Executive Committee. Mr. Santos has more than 25 years of experience in manufacturing diagnostics and medical devices. Prior to joining QIAGEN, he was Senior Vice President, Americas Operations & Global Third Party Products, at bioMérieux in St. Louis, Missouri, where he oversaw since 2013 all manufacturing and supply operations in the Americas. He has worked in international roles in China, Europe and the U.S., and previously served as Vice President Operations at Reliable Biopharmaceutical in the U.S. and at Hovione Pharmasciencia in Portugal, China and the U.S. After studying chemical engineering at the Nova University of Lisbon, School of Science and Technology, he earned an MBA at Rutgers University.



**Dr. Thomas Schweins**

Senior Vice President, Life Sciences Business Area

Gender: Male

Dr. Thomas Schweins joined QIAGEN in 2004 as Vice President Corporate Strategy and was appointed Vice President Marketing & Strategy in 2005, where he was deeply involved in managing the global business toward Life Science customers. In late 2011, Dr. Schweins assumed responsibility for Human Resources and initiated a multi-year transformation process to increase efficiency and effectiveness of the function. In 2017, Dr. Schweins took over the leadership of the Life Science Business Area and

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

Corporate Governance Report

Environmental, Social and Governance

Financial Results

**Appendix**

consequently resigned from his role as head of HR. Dr. Schweins came to QIAGEN from The Boston Consulting Group. He previously worked as Technology Manager, and later as an Assistant to the Management Board at Hoechst / Aventis. Dr. Schweins earned an M.Sc. Degree in Biochemistry from the University of Hanover. He obtained his Ph.D. at the Max Planck Society and received an M.Sc. from the University of Southern California in Los Angeles, where he studied Business Administration and Chemistry.



**Dr. Jonathan Sheldon**

Senior Vice President, QIAGEN Digital Insights Business Area

Gender: Male

Dr. Jonathan Sheldon joined QIAGEN in 2018 as Senior Vice President, QIAGEN Digital Insights Business Area. He leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights. Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the Executive Committee. Previously, he established the bioinformatics group and served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as providing leadership in software firms serving the life science and healthcare sectors. He serves on the Board of Directors of the Drug Information Association (DIA). He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.



**Jean-Pascal Viola**

Senior Vice President, Head of Molecular Diagnostics Business Area and Corporate Business Development

Gender: Male

Jean-Pascal Viola joined QIAGEN in 2005 and has worked in increasing positions of responsibility in Corporate Business Development until he was named in 2015 to the role of Senior Vice President, Corporate Business Development. In October 2019, Mr. Viola was appointed member of the Executive Committee and took on additional responsibilities for the Molecular Diagnostics Business Area, which involves QIAGEN's activities supporting customers in clinical healthcare, and transitioned during this period to focus solely on Molecular Diagnostics beginning in early 2022. Prior to joining QIAGEN, Mr. Viola served as President and CEO of Nextal Biotechnologies Inc., a provider of technologies for protein crystallization, and when QIAGEN acquired Nextal in 2005 he joined as Director of Protein Crystallization. Moving to Business Development in 2007, Mr. Viola led efforts in Asia-Pacific, the Americas, Global M&A and Corporate Ventures. He completed a Bachelor of Science in Biochemistry from the University of Montreal, Canada.

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**
**Corporate Governance Report**
**Environmental, Social and Governance**
**Financial Results**
**Appendix**

## Common Shares

### Market Environment

Stock markets maintained their upward momentum into 2021 continuing growth trends that started during the second half of 2020. This growth was aided by monetary policies enacted in advanced economies to mitigate economic uncertainties and provide liquidity to market participants during the continued COVID-19 pandemic. The global economic recovery fueled by vaccine production and distribution to many countries around the world remained on track despite the emergence of COVID-19 variants during the year. Market benchmarks for the year were strong in 2021. The S&P 500 index in the United States finished up 26.9% in 2021. The DAX index of the 40 largest companies in Germany rose 15.8% during the year, and Germany's TecDAX, of which QIAGEN is a member, improved by 22.0% for the year.

### Global shares listed in the U.S. and Europe

QIAGEN's global shares have been registered and traded in the United States since 1996 and are currently traded on the New York Stock Exchange (NYSE). The global shares have also traded in Germany on the Frankfurt Stock Exchange since 1997, and the Prime Standard segment since its launch in 2003. The dual listing of global shares on NYSE and the Frankfurt exchange offers advantages for QIAGEN, our shareholders and employees, enhancing liquidity, and increasing the potential market opportunity to attract investors, particularly those in the U.S. that can only invest in U.S. dollar-denominated investments. Unlike American Depositary Receipts (ADRs), QIAGEN's global shares provide equal rights for all shareholders and can be traded on either exchange, in U.S. dollars or euros.

### Share Price and Liquidity

QIAGEN's share price increased 5.2% in U.S. dollars to \$55.58 on the NYSE and rose 15.4% in euros to EUR 48.99 on the Frankfurt Stock Exchange (XETRA). Performance was influenced by the effects of the COVID-19 pandemic and initiatives to expand the business post-pandemic. Our shares continued to offer high liquidity, with average daily trading volume of approximately 1.4 million in 2021 (about 0.8 million on the NYSE and other U.S. trading venues, and about 0.6 million on the Frankfurt Stock Exchange (XETRA) and other German exchanges). QIAGEN continued its commitment to disciplined capital allocation and shareholder returns. In 2021, QIAGEN repurchased 1.9 million QIAGEN shares on the Frankfurt Stock Exchange, under a program announced in July 2021. This program ended October 29, 2021. Since 2019, a total of 5.2 million shares were repurchased for a total value of EUR 204.4 million at the times of the purchases. As of December 31, 2021, the free float, which affects weighting of QIAGEN shares in various indices, was approximately 99%.

### Shareholder Structure

QIAGEN has a global investor base comprised of more than 600 identified institutional investors, including about half in North America, about one-third in Europe and the remaining shares in the rest of the world. Members of the Managing Board and the Supervisory Board, in total, own less than 1% of QIAGEN's outstanding common shares at the end of 2021.

### Annual Shareholder Meeting

At the Annual General Meeting on June 29, 2021, in Venlo, the Netherlands, shareholders voted on a number of annually recurring items as well as the Remuneration Policy of the Managing Board. Many of the annually recurring items were approved with majorities above 95% of the shares represented at the meeting. Shareholders present or represented at the meeting held approximately 180.3 million shares, 78.1% of QIAGEN's approximately 230.8 million issued shares as of the record date for the meeting. Details of attendance and voting results are available at [corporate.QIAGEN.com](https://corporate.qiagen.com).


### Investor Relations and Engagement with Shareholders

QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our performance, strategy and future prospects, as well as our vision and mission. Due to the continued COVID-19 pandemic, most discussions with investors were held virtually during 2021 including individual calls, roadshows and investor conferences.

- Overview**
- Supervisory Board Report
- Executive Committee
- Common Shares
- Management Report**
- Corporate Governance Report**
- Environmental, Social and Governance**
- Financial Results**
- Appendix**

### QIAGEN Share Price Development and Average Trading Volume - NYSE 2021

	<b>2021</b>
Year-end price	\$55.58
High	\$59.00
Low	\$45.58
Average daily trading volume (in million shares)	0.79



### QIAGEN Share Indices and Historic Prices - US

Effective January 10, 2018, our Common Shares began trading on the New York Stock Exchange (NYSE) under the symbol QGEN. Prior to that, from July 3, 2006, until January 9, 2018, our Common Shares were traded on the NASDAQ Global Select Market under the symbol QGEN. Previously, since February 15, 2005, our Common Shares had been quoted on the NASDAQ National Market under the symbol QGEN. Prior to that, since June 27, 1996, our Common Shares had been quoted on the NASDAQ National Market under the symbol QGENF.

The following tables set forth the annual high and low sale prices for the last five years, the quarterly high and low sale prices for the last two years, and the monthly high and low sale prices for the last six months of our Common Shares on the NYSE and NASDAQ Global Select, as applicable.



**Overview**
[Supervisory Board Report](#)
[Executive Committee](#)
[Common Shares](#)
**Management Report**
**Corporate Governance Report**
**Environmental, Social and Governance**
**Financial Results**
**Appendix**

	High (\$)	Low (\$)
Annual:		
2017	36.34	27.40
2018	39.45	30.78
2019	43.16	25.04
2020	55.27	32.97
2021	59.00	45.58
Quarterly 2020:		
First Quarter	42.41	32.97
Second Quarter	44.41	39.05
Third Quarter	52.86	42.48
Fourth Quarter	55.27	45.33
Quarterly 2021:		
First Quarter	59.00	45.72
Second Quarter	52.83	45.58
Third Quarter	56.91	45.95
Fourth Quarter	58.00	50.08
Quarterly 2022:		
First Quarter (through March 9)	55.12	41.32
Monthly:		
October 2021	56.33	50.08
November 2021	58.00	52.53
December 2021	56.18	53.26
January 2022	55.12	47.12
February 2022	51.30	46.76
March 2022 (through March 9)	50.40	41.32

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**


**Financial Results**

**Appendix**

**QIAGEN Share Price Development and Average Trading Volume - Frankfurt Stock Exchange (XETRA) 2021**

	2021
Year-end price	€48.99
High	€51.56
Low	€37.38
Average daily trading volume (in million shares)	0.56

**German Share Prices**



**QIAGEN Share Indices and Historic Prices - Germany**

From September 25, 1997, to December 31, 2002, our Common Shares were traded on the Frankfurt Stock Exchange Neuer Markt under the symbol QIA and with the security code number 901626. As of January 1, 2003, the trading of our Common Shares was transferred to the Prime Standard Segment of the Frankfurt Stock Exchange. QIAGEN is a member of DAX effective September 20, 2021, due to a reorganization of German stock market indices. Prior to that, QIAGEN was a member of the MDAX since September 24, 2018. This reorganization in September 2021 included expansion of the DAX index from 30 to the 40 largest companies in Germany based on market capitalization. Also on this date, the MDAX was reduced from the 60 largest companies excluding DAX listed companies to 50.

**Overview**

Supervisory Board Report

Executive Committee

Common Shares

**Management Report**
**Corporate Governance Report**
**Environmental, Social  
and Governance**
**Financial Results**
**Appendix**

The following table sets forth the annual high and low sale prices for the last five years, the quarterly high and low sale prices for the last two years, and the monthly high and low sale prices for the last six months of our Common Shares on the Prime Standard.

	High (EUR)	Low (EUR)
Annual:		
2017	31.52	25.41
2018	34.05	25.22
2019	39.19	22.54
2020	46.95	29.55
2021	51.56	37.38
Quarterly 2020:		
First Quarter	38.75	29.55
Second Quarter	39.80	36.11
Third Quarter	45.44	37.92
Fourth Quarter	46.95	36.00
Quarterly 2021:		
First Quarter	46.45	38.84
Second Quarter	44.02	37.38
Third Quarter	48.05	38.73
Fourth Quarter	51.56	43.06
Quarterly 2022:		
First Quarter (through March 9)	49.34	37.95
Monthly:		
October 2021	49.22	43.06
November 2021	51.56	45.53
December 2021	49.84	47.09
January 2022	49.34	41.16
February 2022	45.25	41.22
March 2022 (through March 9)	45.36	37.95

**Overview**

- Supervisory Board Report
- Executive Committee
- Common Shares

**Management Report**

**Corporate Governance Report**

**Environmental, Social and Governance**


**Financial Results**

**Appendix**


**Key Share Data**

	2021
Year-end market capitalization (in \$ million)	12,621
Year-end market capitalization (in € million)	11,124

**2021 Shareholder Structure by Geography**



**2021 Shareholder Structure by Investor Type**



Source: QIAGEN Shareholder ID